• Wuhan HHD S Nootropics Series Powder CAS 314728-85-3 Sunifiram
  • Wuhan HHD S Nootropics Series Powder CAS 314728-85-3 Sunifiram
Wuhan HHD S Nootropics Series Powder CAS 314728-85-3 Sunifiram
  • Wuhan Hengheda Pharm Co.,Ltd
  • China
  • Immediately after payment
  • 100kg/month

Sunifiram (DM-235) is a synthetic derivative of piracetam, although due to breaking the pyrrolidone backbone Sunifiram is no longer in the racetam class of drugs (yet by being derived from them, Sunifiram is still commonly associated with this class).
Sunifiram has mechanisms similar to nefiracetam in the hippocampus, and similar to that drug sunifiram shows anti-amnesiac properties and is potentially a cognitive enhancer. Sunifiram anti-amnesiac activity is several orders of magnitude greater than piracetam on a per weight basis, and preliminary evidence suggest it has a similarly low toxicity profile.
Sunifiram is known as an AMPAkine due to exerting most of its actions via the AMPA receptor (one of the three main subsets of glutamate receptors, alongside NDMA and kainate). This enhancement of AMPA function seems to also rely on enhancing signalling via the glycine binding site of NMDA receptors, although one minimal signalling goes through the NMDA receptor then the benefits on AMPA receptors seem dose-dependent.


Nootropics are a category of drugs that are often referred to as “Smart Drugs.” This title is earned because these drugs have provided benefits in the areas of attention span, cognitions, recall and overall memory enhancements that can improve one’s mental performance. Sunifiram is one such drug. Unlike many of the drugs that fall under the heading of nootropics are all from the Racetam family except in the case of Sunifiram. Sunifiram is referred to as an ampakine because it gains its effectiveness through the increasing glycine receptor binding.


While the effects of Sunifiram show many positive aids in increasing acetylcholine levels, which can be extremely beneficial in many dementia and Alzheimer’s disease sufferers. However, studies have yet to determine if its effects can be predictable. As with many drugs, their effectiveness can differ from person to person. While many may reap great rewards from Sunifiram, others may not benefit as much. According to the researchers, it is a matter of individual needs, conditions, and lifestyle all plays a role. That said more research is necessary to determine the future applications of particular nootropic option. The effects of Sunifiram on the sufferers of Alzheimer’s disease have been most promising. Alzheimer’s presents as degeneration the cholinergic system, Sunifiram works to reverse that deficiency and improves the cognition over the short and long-term duration of treatment (Moriguchi & et. al, 2013). However, there are other studies, performed on mice, which appear to reverse the effects of amnesia. Mice whose memories were intentionally diminished were then given doses of Sunifiram, and their memory loss was improved.


Sunifiram is considered to be a safe drug with few or no potential side effects of concern. However, there are some minor side effects that can be mentioned, including headaches, anxiety, insomnia or sleeplessness, and nausea. All of these side effects are treatable and not considered a serious risk to anyone’s health. Because of its marketing as a brain drug and its notable lack of side-effects, the present concern is that people will seek the drug illegally and use the drug without need and in higher doses than would normally be prescribed. Because the drug mimics the effects experienced when one takes amphetamine and methylphenidate, which aid in promoting wakefulness many students are using the drug to improve overall test scores. Unfortunately, studies have yet to show if there is an addictive quality present when taken freely (Mullen, 2014).

That said studies are still being done to determine the overall safety, efficiency and effectiveness of Sunifiram. However, all current studies and preliminary data are showing that there are few side effects, and the treatment seems to be incredibly beneficial in the treatments of serious conditions, like amnesia, Alzheimer’s and Parkinson’s disease. Nootropics may not be the solution to boosting one’s brain power, especially without the advice and overseeing by a doctor, but its applications in aiding people with reestablishing, maintaining, and improving the memories of those who possess conditions that can strip their recall and be freed from some of the mentally debilitating aspects of these illnesses or injuries are important. In the end, the further research in    to Sunifiram and all the Nootropic drugs is worthwhile and potentially beneficial well into the future.


Sunifiram, DM-235, is derived from Piracetam but is not considered a Racetam class chemical due to the chemical structure of Sunifiram. Sunifiram is an ampakine that gains some effectiveness through the increase of the glycine receptor binding in regard to NDMA.

Sunifiram is a piperazine alkaloid that shares a chemical shape of both Unifiram and Sapunifiram. Sunifiram has been shown in a study that after taking it for 7 to 12 days, an increase in potentiation of NDMA receptors is seen. After words, Sunifiram begins to show positive improvement in AMPA receptors as well as acetylcholine (ACh) receptors. It shares a structure based off of Piracetam, although the major difference is that Sunifiram’s pyrrolidine backbone is left open after attaching a piperazine structure to it.

Sunifiram along with Unifiram was shown in a study to help improve the output of acetylcholine to the prefrontal cortex in lab rats, while also having an anti-amnesiac effect, this study suggests that it may be due to DM-235’s effects on the AMPA receptors that cause this. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers (CNS Drug Rev. 2006 Spring;12(1):39-52).

In one study, Sunifiram was found to help increase the long-term potentiation in olfactory bulbectomized mice. Sunifiram was also found to improve short-term memory assessment, Sunifiram did not show any signs of any anti-depression effects. Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice

Do we have the test reports for our products provided by the independent third party?
Every batch of our product was tested by authorized independent third party, Analysis testing center, Shanghai branch, Chinese Academy of Science. We send goods to customers with test report and COA. Our products were also tested by American Analytical Chemistry Laboratories and Chromadex too....more
Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy

close left right